LIVE
AMWL
Amwell (American Well Corporation) · Health Care - Telehealth Platform
$8.43
+7.66% this month
VERSUS
⟷
COMPARE
HIMS
Hims & Hers Health, Inc. · Health Care - Consumer Telehealth & Wellness
$35.47
+58.07% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
AMWL
3
HIMS
1
Comparison scoreboard
AMWL LEADS 3/5AI Score
AMWL 22.0
HIMS ✓35.1
1Y Return
AMWL ✓+23.79%
HIMS -41.92%
Fwd P/E
AMWL ✓-5.02
HIMS 39.85
Target Up.
AMWL ✓-11.03%
HIMS -22.97%
Op. Margin
AMWL N/A
HIMS N/A
Metrics last refreshed: 6/20/2026
Quick take
AMWL vs HIMS Stock Comparison: AI Score, Valuation, Performance and Upside
AMWL is a B2B telehealth infrastructure company serving health systems and payers navigating post-COVID demand normalization, while HIMS is a consumer-facing digital health brand offering telehealth consultations and wellness subscriptions targeting destigmatized health categories. Both are in telehealth but serve fundamentally different customer types.
AMWL vs HIMS compares enterprise B2B telehealth infrastructure against a consumer-facing digital health brand, both competing in the broader telehealth market but with completely different business models and customers.
Live analysis · updated 6/20/2026
AMWL holds the edge across 3 of 5 key metrics in this comparison. AMWL leads on both 1-year return (+23.79%) and forward P/E (-5.02x vs 39.85x for HIMS), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for AMWL (-11.03%) than for HIMS (-22.97%).
Normalized 1Y performance
AMWL
HIMS
Recent returns
AMWL
HIMS
Analyst price targets & sentiment
AMWL · 5 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.7/5.0)
Price target range
analyst low$6.50
analyst high$9.00
analyst mean$7.50
current price$8.43
-11.0% upside to analyst mean
HIMS · 14 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.8/5.0)
Price target range
analyst low$21.00
analyst high$39.00
analyst mean$27.32
current price$35.47
-23.0% upside to analyst mean
Who should consider this stock?
AMWL may suit investors who:
- →Want enterprise telehealth infrastructure exposure through health system and payer relationships
- →See value in Amwell's Converge platform modernization driving customer retention and new wins
- →Are comfortable with a slower-growth, more defensive enterprise B2B telehealth investment
HIMS may suit investors who:
- →Want consumer digital health brand exposure across men's and women's wellness categories
- →See GLP-1 weight management as a significant near-term growth catalyst for Hims & Hers
- →Value the recurring subscription model and high customer lifetime value from prescription wellness products
Performance & AI score
| Metric | AMWL | HIMS |
|---|---|---|
| AI score | 22.0 | 35.1 |
| AI rank | #4430 | #1626 |
| Latest close | $8.43 | $35.47 |
| 1M return | +7.66% | +58.07% |
| 6M return | +79.36% | +1.43% |
| 1Y return | +23.79% | -41.92% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMWL | HIMS |
|---|---|---|
| 1Y ago | $12.38K (+23.8%) started 2025-06-18 | $5.81K (-41.9%) started 2025-06-18 |
| 5Y ago | $312.69 (-96.9%) started 2021-06-18 | $31.95K (+219.5%) started 2021-06-18 |
| 10Y ago | $182.7 (-98.2%) started 2020-09-17 | $36.19K (+261.9%) started 2019-09-13 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | AMWL | HIMS |
|---|---|---|
| Market cap | $140.85M | $8.21B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -5.02 | 39.85 |
| Price/Sales | 0.59 | 3.46 |
| EV/Revenue | -0.08 | 3.23 |
| Analyst target | $7.50 | $27.32 |
| Target upside | -11.03% | -22.97% |
Growth, profitability & risk
| Metric | AMWL | HIMS |
|---|---|---|
| Revenue growth | -17.90% | 3.80% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -4.96% | +7.36% |
| Operating margin | N/A | N/A |
| Profit margin | -37.02% | -0.56% |
| ROIC proxy | -31.84% | -2.66% |
| Return on equity | -31.84% | -2.66% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.70 | 2.40 |
| Debt/equity | 1.65 | 253.72 |
| Current ratio | 3.09 | 1.69 |
| Quick ratio | 2.83 | 1.46 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
AMWL max drawdown57.81%
HIMS max drawdown78.06%
AMWL max wkly drop22.77%
HIMS max wkly drop32.71%
5Y risk snapshot
AMWL max drawdown98.62%
HIMS max drawdown78.88%
AMWL max wkly drop38.27%
HIMS max wkly drop39.06%
10Y risk snapshot
AMWL max drawdown99.56%
HIMS max drawdown87.29%
AMWL max wkly drop38.27%
HIMS max wkly drop39.06%
Performance metrics by period
| Period | Metric | AMWL | HIMS |
|---|---|---|---|
| 1Y | Growth | +23.79% | -41.92% |
| CAGR | +23.81% | -41.94% | |
| Sharpe ratio | 0.57 | -0.12 | |
| Max drawdown | 57.81% | 78.06% | |
| Max daily drop | 10.50% | 34.63% | |
| Max wkly drop | 22.77% | 32.71% | |
| 5Y | Growth | -96.87% | +219.55% |
| CAGR | -50.00% | +26.16% | |
| Sharpe ratio | -0.59 | 0.64 | |
| Max drawdown | 98.62% | 78.88% | |
| Max daily drop | 23.08% | 34.63% | |
| Max wkly drop | 38.27% | 39.06% | |
| 10Y | Growth | -98.17% | +261.94% |
| CAGR | -50.15% | +20.95% | |
| Sharpe ratio | -0.57 | 0.57 | |
| Max drawdown | 99.56% | 87.29% | |
| Max daily drop | 23.08% | 34.63% | |
| Max wkly drop | 38.27% | 39.06% |
Business comparison
| Category | AMWL | HIMS |
|---|---|---|
| Company | Amwell (American Well Corporation) | Hims & Hers Health, Inc. |
| Sector | Health Care - Telehealth Platform | Health Care - Consumer Telehealth & Wellness |
| Industry | N/A | N/A |
| Core business | Amwell provides a telehealth technology platform to health systems, payers, and employers, enabling healthcare organizations to offer virtual care visits across primary care, behavioral health, and specialty care, with its Converge platform as the next-generation infrastructure. | Hims & Hers provides telehealth services and prescription wellness products directly to consumers, addressing men's health (hair loss, sexual health, mental health) and women's health (skincare, birth control, menopause) through a branded digital health and wellness platform. |
| Investor focus | Investors track Amwell's subscription revenue from health system and payer clients, Converge platform adoption, and the company's ability to sustain growth after COVID-era telehealth demand normalization. | Investors track Hims & Hers' subscriber growth, average order value expansion into new health categories, GLP-1 weight loss product opportunities, and revenue per subscriber as category breadth grows. |
AMWL strengths
- →Deep relationships with major health systems and payers as an enterprise telehealth infrastructure provider
- →Converge next-generation platform provides a more extensible, modern technical foundation for healthcare partners
- →Enterprise B2B model provides more predictable subscription revenue than consumer telehealth models
HIMS strengths
- →Strong consumer brand with destigmatized, direct-to-consumer approach to sensitive health topics
- →Subscription model with recurring prescription refills creates predictable revenue
- →GLP-1 compounding and weight management category expansion provides a significant near-term growth opportunity
Risks to watch — AMWL
- →COVID-era telehealth surge has significantly moderated, pressuring volume and revenue growth
- →Competed against large health system-owned solutions and tech giants (Microsoft, Epic) expanding into telehealth infrastructure
- →Path to GAAP profitability requires operating leverage that has been difficult to achieve at current revenue levels
Risks to watch — HIMS
- →GLP-1 compounding revenue faces regulatory risk as FDA-approved brand availability affects compounding market access
- →Consumer health brand building requires ongoing marketing investment to sustain subscriber acquisition
- →Must continue expanding into new health categories to sustain growth as original hair loss/sexual health categories mature
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →